Judge gives final approval to Bayer's $7.25 billion Roundup settlement

RUKUS· · 4h ← 27h
Go Rogue

A court in St. Louis, Missouri has given final approval to Bayer's $7.25 billion settlement of nationwide lawsuits claiming its weedkiller Roundup caused non-Hodgkin lymphoma. On November 20, 2026, St. Louis Circuit Judge Timothy Boyer approved the deal, which had won preliminary approval in March 2026 and was reached in principle months before it was announced. Under the settlement, people who have been or will be diagnosed with non-Hodgkin lymphoma, which plaintiffs link to Roundup's main ingredient glyphosate, can receive between $10,000 and $165,000 each. Bayer is to pay the $7.25 billion over two decades, giving the company financial certainty against litigation costs that had led it to consider pulling Roundup from US agricultural markets, and the deal includes $600 million in legal fees. In his judgment, Boyer wrote there was a risk Bayer would have filed for bankruptcy protection had the settlement been rejected. Some lawyers for the cancer patients contend the payouts are too small, while others argue the deal is better than receiving nothing. The approval is subject to appeal.

  1. The settlement was reached in principle months before the court-approved deal was announced.

    Christopher Seeger said in May that more than 40,000 people could be covered by the settlement.

  2. In his ruling, Judge Timothy Boyer said the court "fully and finally approves the Settlement Agreement in its entirety."

    Christopher Seeger said the path to successful litigation had "narrowed" since the US Supreme Court's June ruling that shielded Bayer from failure-to-warn claims in state courts.

  3. A court in St. Louis, Missouri gave the nationwide Roundup class settlement preliminary approval in March 2026.

    On November 20, 2026, St. Louis Circuit Judge Timothy Boyer gave final approval to Bayer's $7.25 billion settlement of nationwide lawsuits claiming Roundup caused non-Hodgkin lymphoma.

    Plaintiffs' lawyer Christopher Seeger said the approval "delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice."

    Bayer said in February that the compensation includes no admission of responsibility or fault.

  4. Bayer is to pay the $7.25 billion over two decades, giving the company financial certainty against litigation costs that had led it to consider pulling Roundup from US agricultural markets.

    The approved settlement includes $600 million in legal fees.

    Judge Timothy Boyer wrote in his judgment that there was a risk Bayer would have filed for bankruptcy protection had the settlement been rejected.

    Some lawyers for the cancer patients contend the settlement payouts are too small, while others argue the deal is better than receiving nothing.

    Bayer denies that Roundup causes cancer.

  5. The final approval of the $7.25 billion settlement is subject to appeal.

    Bayer representatives said the settlement was "designed to resolve current and future" claims and closes the courthouse doors to anyone else seeking restitution over Roundup.

  6. Under the settlement, people who have been or will be diagnosed with non-Hodgkin lymphoma, which plaintiffs link to Roundup's main ingredient glyphosate, can receive between $10,000 and $165,000 each.

    Bayer chief executive Bill Anderson called the approval "a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup litigation."

    Judge Timothy Boyer called the payouts "fair and adequate" and the settlement "among the largest in the history of mass tort personal-injury class action settlements."

Sign in with subscription

Free during the beta.

Clear all notifications?

Your bells stay on. Only this list empties.